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Abstract
Background: Gastrointestinal cancer antigen CA19-9
is known as a valuable marker for the management
of patients with pancreatic cancer.
Methods: The analytical and clinical performance of
the Access GI Monitor assay (Beckman Coulter) was
evaluated on the UniCel DxI 800 Immunoassay Sys-
tem at five different European sites and compared
with a reference method, defined as CA19-9 on the
Elecsys System (Roche Diagnostics).
Results: Total imprecision (%CV) of the GI Monitor
ranged between 3.4% and 7.7%, and inter-laboratory
reproducibility between 3.6% and 4.0%. Linearity
upon dilution showed a mean recovery of 97.4%
(SDq7.2%). Endogenous interferents had no influ-
ence on GI Monitor levels (mean recoveries: hemo-
globin 103%, bilirubin 106%, triglycerides 106%).
There was no high-dose hook effect up to 115,000
kU/L. Clinical performance investigated in sera from
1811 individuals showed a good correlation between
the Access GI Monitor and Elecsys CA19-9 (Rs0.959,
slopes1.004, interceptsq0.17). GI Monitor serum
levels were low in healthy individuals (ns267,
medians6.0 kU/L, 95th percentiles23.1 kU/L), higher
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in individuals with various benign diseases (ns550,
medianss5.8–13.4 kU/L, 95th percentiless30.1–195.5
kU/L) and even higher in individuals suffering from
various cancers (ns995, medianss8.4–233.8 kU/L,
95th percentiless53.7–13,902 kU/L). Optimal diagnos-
tic accuracy for cancer detection against the relevant
benign control group by the GI Monitor was found for
pancreatic cancer warea under the curve (AUC) 0.83x.
Results for the reference CA19-9 assay were compar-
able (AUC 0.85).
Conclusions: The Access GI Monitor provides very
good methodological characteristics and demon-
strates an excellent analytical and clinical correlation
with the Elecsys CA19-9. The GI Monitor shows the
best diagnostic accuracy in pancreatic cancer. Our
results also suggest a clinical value of the GI Monitor
in other cancers.
Clin Chem Lab Med 2008;46:600–11.
Keywords: CA19-9 gastrointestinal cancer antigen;
diagnosis; method comparison; pancreatic cancer.
Introduction
Pancreatic cancer accounts for only 2% of the newly
diagnosed cancers per year. Because the overall
median survival is only 3–5 months with a 1-year sur-
vival rate of less than 10% (1), pancreatic cancer ranks
as the fourth leading death cause among cancer dis-
eases (2). More than 80% of the patients are initially
diagnosed at advanced stages of disease, when treat-
ment options are limited to systemic therapies to con-
trol disease-related symptoms and prolong survival
(3, 4). The diagnosis of pancreatic cancer is usually
established based on imaging techniques and sub-
sequent histological confirmation. Desmoplastic stro-
ma reaction is a well-known confounder, particularly
of computed tomography, which makes it difficult to
differentiate normal pancreas, local inflammation and
fibrosis from malignant tissue (5). Therefore, other
surrogate markers for differential diagnosis and esti-
mation of treatment efficacy are needed. For these
purposes, several studies have suggested the deter-
mination of the gastrointestinal cancer antigen CA19-
9 concentration (6–9).
The tumor-associated antigen CA19-9 is the sialy-
lated hapten of the human Lewis Lea blood group
antigen (10), first described by Koprowski et al. in
1979 (11). Individuals with a Le(a–b) phenotype (lacking
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the Lewis-antigen glycosyltranferase) are unable to
synthesize and release CA19-9 (12). Koprowski et al.
defined CA19-9 using the monoclonal antibody 1116-
NS-19-9, which was produced by a mouse spleen
hybridoma immunized with a human colorectal car-
cinoma cell line (11, 13).
CA19-9 is detected in colorectal, gastric and pancre-
atic cancer tissues (80%–90%), but also in liver, gall
bladder, lung, breast and gynecological cancers (8, 9,
14–16). In serum, only low concentrations of the high
molecular, mucinous CA19-9 (molecular weight
900,000 Da) are found physiologically. In contrast,
very high levels (up to 100,000 kU/L) have been
reported in human body secretions, such as bile fluid,
urine, sputum, milk, amniotic fluid and ovarian cysts
(8–10). However, some benign diseases have been
associated with elevated CA19-9 antigen levels,
including particularly non-malignant gastrointestinal
diseases with a cholestatic component, such as liver
cirrhosis, cholangitis, hepatitis and pancreatitis (8, 9,
17–19).
For the diagnosis of pancreatic cancer, CA19-9 is
the marker of choice with a sensitivity of 70%–90% (8,
20–22), particularly in tumors of the pancreatic head.
Because there is no direct correlation of marker levels
with tumor volume, CA19-9 is often (approximately
80%) already released in early tumor stages and
reaches concentrations of more than 500 kU/L in 30%
of the cases. Very high levels ()10,000 kU/L) are
indicative of distant metastases. However, due to the
lacking tumor and organ specificity, the early detec-
tion of pancreatic cancer by a one-time determination
of CA19-9 is not possible (8, 9).
The prognostic value of CA19-9 levels for overall
survival has been shown in various studies for pan-
creatic cancer patients undergoing surgery, as well as
for those receiving systemic chemo- and/or radiother-
apy: pre-therapeutic low CA19-9 concentrations are
associated with a significantly longer survival. Cut-
offs used showed a considerable variation between
200 kU/L and 2000 kU/L and were lower in patients
with early stage pancreatic cancer undergoing sur-
gery (6, 23–25).
The usefulness of CA19-9 for estimation of therapy
efficacy is currently under investigation. Several stud-
ies have reported a close correlation between CA19-
9 kinetics and therapy response, even if they used
different definitions of CA19-9 decrease as criterion
for therapy efficacy (6, 26–31). Stemmler et al. dem-
onstrated CA19-9 decreases during chemotherapy –
independent from their degree – were associated with
longer survival, whereas increasing levels were linked
with poor prognosis (31).
In the present study, a new assay for detection of
CA19-9 antigen was evaluated for its analytical and
clinical performance, and compared with an estab-
lished reference method. This Access GI Monitor
assay is applied on the UniCel DxI 800 Immunoassay
System (Beckman Coulter Eurocenter S.A., Nyon,
Switzerland) and uses the monoclonal antibody C192
as tracer and capture antibody, which recognizes
practically the same epitope (same specificity) as the
Centocor 1116-NS-19-9 monoclonal antibody (Cento-
cor Inc., Horsham, PA, USA). As most of the currently
available assays are based on the original Centocor
antibody, it is challenging to compare the clinical rel-
evance of the new assay using an alternative anti-
body, which in consequence has led to the new name
‘‘Access GI Monitor assay’’.
The present evaluation was performed as a Euro-




Access GI Monitor (CA19-9 antigen) assay on the UniCel
DxI 800 Immunoassay System (Beckman Coulter) The
Access GI Monitor assay is a paramagnetic particle, two-site
immunoenzymatic (‘‘sandwich’’), chemiluminescent immu-
noassay for the quantitative determination of CA19-9 antigen
levels in human serum and plasma using the Access Immu-
noassay Systems. A sample is added to a reaction vessel
along with paramagnetic particles coated with polyclonal
goat anti-biotin antibody, mouse monoclonal-biotin conju-
gate and a buffered protein solution. After incubation in a
reaction vessel, separation in a magnetic field and washing
remove materials not bound to the solid phase. A monoclo-
nal-alkaline phosphatase conjugate is then added. After incu-
bation in a reaction vessel, materials bound to the solid
phase are held in a magnetic field, while unbound materials
are washed away. Then, the chemiluminescent substrate
Lumi-Phos 530 is added to the vessel and light generated by
the reaction is measured with a luminometer. The light pro-
duction is directly proportional to the concentration of CA19-
9 antigen in the sample. The amount of analyte in the sample
is determined from a stored, multi-point calibration curve.
Samples can be accurately measured within the analytic
range of the lower limit of detection and the highest calibra-
tor value (approximately 0.8–2000 kU/L).
For calibration, Access GI Monitor Calibrators (Cat. No.
387688: S0–S5, 2.5 mL/vial) were used. The Access GI Mon-
itor Calibrators are provided at six levels – zero and approx-
imately 30, 90, 300, 900 and 2000 kU/L. Controls, Bio-Rad
Lyphochek Tumor Marker Controls (Cat. No. 580 Bilevel,
6=2 mL; Bio-Rad Laboratories, Munich, Germany), were run
in duplicates every day of the study.
CA19-9 assay on Elecsys 2010 Immunology System (Roche
Diagnostics GmbH) The CA19-9 assay is an electrochemo-
luminescence immunoassay for the quantitative determina-
tion of CA19-9 antigen levels in human serum and plasma
using the Elecsys 2010/1010 and Modular Analytics E170
Immunology Systems (Roche Diagnostics, Penzberg, Ger-
many). The assay is based on a sandwich principle with the
monoclonal antibody 1116-NS-19-9: 10 mL of sample, a
biotinylated monoclonal CA19-9-specific antibody, and the
monoclonal antibody labeled with a ruthenium complex
form a sandwich complex. After addition of streptavidin-
coated microparticles, the complex becomes bound to the
solid phase via interaction of biotin and streptavidin. The
reaction mixture is aspirated into the measuring cell, where
the microparticles are magnetically captured onto the sur-
face of the electrode. Unbound substances are then removed
with ProCell buffer. Application of a voltage to the electrode
then induces chemiluminescent emission that is measured
by a photomultiplier tube. Results are determined via a cal-
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ibration curve which is instrument-specifically generated by
two-point calibration and a master curve provided by the
manufacturer via the reagent pack barcode.
Samples can be accurately measured within the analytic
range of 0.6–1000 kU/L.
For calibration, Elecsys CA19-9 CalSet (Cat. No. 11776215,
for 4=1 mL) was used. Controls, Elecsys PreciControl Tumor
Markers 1 and 2 (Cat. No. 11776452, 2=3 mL), were run in
duplicates every day of the study.
Analytical evaluation
The analytical performance of the Access GI Monitor assay
was evaluated by all five centers in parallel, in particular
imprecision, inter-laboratory reproducibility, minimum
detectable concentration and linearity upon dilution. The
influence of endogenous interferents and high-dose hook
effect was tested in the laboratories of Munich, Barcelona
and Aachen; interferences of sample type and sample stor-
age were only tested in Munich.
Imprecision Two controls (Bio-Rad) and three human
serum pools prepared by each center (32), including a low,
medium and high concentration pool, were tested in tripli-
cate, with two runs per day for at least 10 days according to
the guidelines of the CLSI (Clinical and Laboratory Standards
Institute, formerly NCCLS; document NCCLS-EP5-A). Data
analysis included calculation of within-run and total impre-
cision and was performed by Acomed Statistics, Leipzig,
Germany.
Inter-laboratory reproducibility Inter-laboratory reproduci-
bility was evaluated using the two controls across the five
evaluation sites.
Minimum detectable concentration The minimum detect-
able concentration was defined as the GI monitor concentra-
tion corresponding to a signal two standard deviations
above the mean value of 10 replicates of the S0 calibrator
tested on each of 3 days.
Linearity upon dilution A total of 32 samples, with 13 of
them above the assay dynamic range ()2000 kU/L) and 19
of them between 1000 and 2000 kU/L, were diluted with the
appropriate Access GI Monitor diluent to obtain a minimum
of four dilutions within the assay dynamic range. Dilutions
were prepared separately in one to two steps using calibrat-
ed pipettes and were carried out in four replicates. Recov-
eries were calculated with respect to the highest
concentration in the dynamic range.
Sample type interference Samples were obtained from 10
patients with unsuspicious laboratory findings, one serum in
tubes with kaolin, one lithium-heparinate plasma, one EDTA
plasma and one citrate plasma. Sample type interference
was tested in duplicates. Recoveries were calculated with
respect to the concentration in the serum sample.
Sample storage interference Samples from seven of these
patients were measured natively and after storage at 48C and
–208C for 1 day. Both storage modalities were compared
with the native measurements.
Further, serum and lithium-heparinate plasma samples of
the 10 patients were stored at –208C for 6 months and meas-
urements were compared with the original –208C data to test
the long-term stability.
Endogenous interferents The influence of bilirubin, hemo-
globin and triglycerides was tested on a human serum pool
with high CA19-9 concentrations. The serum pool was dilut-
ed with a serum containing high bilirubin concentrations
()0.062 mmol/L), with a serum with high hemoglobin (ca.
0.855 mmol/L; normal serum spiked with hemolyzed blood
sample) and with a serum with high triglyceride concentra-
tion ()0.006 mmol/L). These test solutions were tested with
the Access GI Monitor assay and compared to the control
solutions obtained from the same pool diluted in the same
way with the Sample Diluent A (Catalog Number 81908)
instead of the interfering substance. Each test solution and
each control solution were assayed 10 times in constantly
decreasing proportions. Recoveries were calculated with
respect to the concentration of the undiluted serum pool.
Additionally, 10 samples with high known rheumatoid
factor concentration were tested in duplicate.
High-dose hook effect Serial 10-fold dilutions of 11 differ-
ent samples with very high CA19-9 concentrations above
30,000 kU/L were tested. Recoveries were calculated with
respect to the highest concentration in the dynamic range.
Clinical performance
The clinical performance of the Access GI Monitor assay was
evaluated by two sites (Munich and Barcelona). All clinical
samples were sent to the Institute of Clinical Chemistry of
the University Hospital Munich, to be tested using the
Access GI Monitor assay on the UniCel DxI 800 Immuno-
assay System (Beckman Coulter) and compared to the ref-
erence CA19-9 assay on the Elecsys 2010 Immunology
System (Roche Diagnostics).
Healthy individuals The reference interval for the GI Mon-
itor was established from 267 samples, including 113 sera
from men and 154 sera from non-pregnant women. Median
age was 39.4 years (range 17–81 years). The subject inclu-
sion/exclusion criteria were as follows:
• normal, apparently healthy subjects (evaluated clinically
and by clinical chemistry parameters),
• adults older than 18 years were tested,
• no personal history of cancer disease, renal failure or
liver disease.
Age and sex were mandatory for all samples enrolled.
Samples with hemolysis, bilirubin or lipemia were excluded.
Individuals with benign diseases GI Monitor results were
determined in a total of 549 individuals diagnosed with
benign diseases, among them 155 benign gastrointestinal
diseases (ulcerous colitis, Crohn’s disease, liver cirrhosis,
hepatitis, pancreatitis, cholelithiasis, etc.), 44 benign lung
diseases (tuberculosis, sarcoidosis, pneumonia, etc.), 109
benign gynecological diseases (ovarian cysts, endometrio-
sis, uterine leiomyoma, etc.), 148 benign breast diseases, 66
benign urological diseases (nephrolithiasis, renal failure,
etc.) and 27 other benign diseases, and compared with the
reference system.
Individuals with malignant diseases GI Monitor results
were determined in a total of 995 individuals diagnosedwith
cancer diseases and were compared with the reference
method. The cancer diseases included 62 pancreatic cancers,
26 gastric cancers, 58 hepatocellular cancers, 113 colorectal
cancers, 82 lung cancers, 81 ovarian cancers, 57 other gyne-
cological cancers, 416 breast cancers, 57 urological cancers
(bladder and kidneys) and 43 prostate cancers.
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Figure 1 Linearity upon dilution.
Samples with high GI Monitor levels were diluted by one to
two steps and recoveries were calculated for various dilution
steps.
All samples were obtained from patients with active dis-
ease, typically before surgery as first treatment modality, or
in some cases at time of recurrent disease.
Statistical analysis
The GI Monitor assay and reference method were compared
using regression equations according to Passing and Bablok.
Normalized differences from mean values were calculated
according to Bland and Altman.
In healthy individuals, the frequency distribution for the GI
Monitor and reference method was defined including 25th
percentile, median, mean and upper reference limit (URL) of
a normal population at 95th, 97.5th and 99th percentiles.
In all studied groups, distribution of the GI Monitor and
reference method concentrations were presented graphical-
ly, as well as statistically (median, range, 95th percentile).
The analysis of the sensitivity/specificity for pancreatic
cancer included receiver operator characteristics (ROC)
curves, using benign gastrointestinal diseases as the control
group. Similarly, ROC curves were established for lung can-
cer vs. benign lung diseases, colorectal cancer vs. benign
gastrointestinal diseases, breast cancer vs. benign breast
diseases, and ovarian cancer vs. benign gynecological dis-
eases. Further, at 95% specificity against the respective
benign control group, the sensitivity for each cancer type
was calculated, and also the area under the curve (AUC) of
the corresponding ROC curves.
Results
Analytical evaluation
Imprecision Within-run imprecision of the low con-
trol (8.6–9.3 kU/L) ranged in the various centers
between 2.6% and 5.2%, and of the high control
(32.2–35.2 kU/L) between 2.6% and 4.4%. Within-run
imprecision of the low serum pools (ranging from 4.8
to 44.0 kU/L) was between 2.3% and 4.4%, of the
medium serum pools (ranging from 106 to 404 kU/L)
between 2.1% and 4.7%, and of the high serum pools
(ranging from 447 to 1652 kU/L) between 2.4% and
5.0%.
Total imprecision of the low control (8.6–9.3 kU/L)
ranged in the various centers between 4.4% and 7.7%,
and of the high control (32.2–35.2 kU/L) between 4.6%
and 7.7%. Total imprecision of the low serum pools
(4.8–44.0 kU/L) was between 4.8% and 6.4%, of the
medium serum pools (106–404 kU/L) between 3.7%
and 6.3%, and of the high serum pools (447–1652
kU/L) between 3.4% and 6.1%.
Inter-laboratory reproducibility Inter-laboratory impre-
cision of the low control (8.6–9.3 kU/L) was found to
be 3.6%, and of the high control (32.2–35.2 kU/L)
4.0%.
Minimum detectable concentration In four centers,
the minimum detectable concentration was found to
be -0.8 kU/L, and in one center -1.05 kU/L. All these
results are in the very low range which has no clinical
relevance.
Linearity upon dilution Mean recovery of all dilu-
tions in all centers was 97.4%, with a standard devi-
ation of 7.2% (minimum 79.7%, maximum 121%)
(Figure 1).
Sample type interference Samples from 10 patients
with unsuspicious laboratory findings were tested on
sample type interference. GI Monitor measurements
in kaolin serum and lithium-heparinate plasma were
very comparable. Mean recovery in heparinate plas-
ma was 100%, with a standard deviation of 3.4% (min-
imum 94.4%, maximum 106%). GI Monitor values in
EDTA plasma and citrate plasma were very compar-
able and lower than GI Monitor values in serum. For
EDTA plasma, mean recovery was 77.5%, with a stan-
dard deviation of 2.4% (minimum 72.9%, maximum
80.3%). For citrate plasma, mean recovery was 79.6%,
with a standard deviation of 3.9% (minimum 73.9%,
maximum 85.8%).
Sample storage interference Samples from seven of
these patients were measured natively, after storage
at 48C and at –208C for 1 day. Both storage conditions
tested did not affect the GI Monitor values. After stor-
age at 48C, mean recovery was 100.0%, with a stan-
dard deviation of 4.3% (minimum 91.5%, maximum
104.3%). After storage at –208C, mean recovery was
100%, with a standard deviation of 3.8% (minimum
94.9%, maximum 104.5%).
In addition, serum and lithium-heparinate plasma
samples of the 10 patients were stored at –208C for
6 months and measurements were compared with the
original –208C data to test the long-term stability.
Again, storage had no influence on marker levels.
When serum was stored at –208C for 6 months, mean
recovery was 100.7%, with a standard deviation of
6.9% (minimum 91.5%, maximum 109%). When lithi-
um-heparinate plasma was stored at –208C for
6 months, mean recovery was 105%, with a standard
deviation of 10.6% (minimum 89.7%, maximum
126.9%).
Endogenous interferents The potentially confound-
ing impact of endogenous interferents, such as hemo-
globin, bilirubin and triglycerides was tested at two
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Figure 3 Influence of high-dose hook effect.
Samples with extremely high GI Monitor levels ()18,000
kU/L) were diluted by 1:10 steps.
Figure 2 Influence of endogenous interferences.
Samples were spiked with various concentrations of hemo-
globin (), bilirubin (m) and triglycerides (d) and recoveries
of GI Monitor levels were calculated for various dilution
steps.
centers. Stepwise dilution of a serum pool having
high CA19-9 levels with a serum sample with high
concentrations of the relevant interferent and, alter-
natively, with sample diluent which was free of any
contamination showed that neither interferent had
any influence on GI Monitor levels.
Dilution with hemoglobin-spiked serum resulted in
a mean recovery of 103%, with a standard deviation
of 10.3% (minimum 78.6%, maximum 123%). There
was no trend of continuously changing GI Monitor
values when increasing amounts of hemoglobin were
added (Figure 2).
Dilution with bilirubin-rich serum showed a mean
recovery of 106%, with a standard deviation of 7.5%
(minimum 84.5%, maximum 115%). There was no
trend of continuously changing GI Monitor values
when increasing amounts of bilirubin were added
(Figure 2).
In the dilution series with triglyceride-rich serum,
one random outlier was identified (recovery of 186%).
If this value was excluded, mean recovery was 106%,
with a standard deviation of 11.1% (minimum 89.1%,
maximum 131%). Despite the outlier, there was no
trend of continuously changing GI Monitor values
when increasing amounts of triglycerides were added
(Figure 2).
Rheumatoid factor In total, 14 serum samples with
high rheumatoid factor concentrations (mean
209.4 kU/L, standard deviation 298.0 kU/L, minimum
26.7 kU/L, maximum 1131 kU/L) were tested on a
potential confounding effect on GI Monitor values.
However, all GI Monitor levels were very low in the
range of healthy individuals. Mean value was 8.9
kU/L, with a standard deviation of 8.6% (minimum 0.8
kU/L, maximum 33.0 kU/L).
High-dose hook effect In total, 11 serum samples
with extremely high CA19-9 levels (18,011–
114,920 kU/L) were tested in dilution series on a
potential high-dose hook effect. As illustrated graph-
ically in Figure 3, in all samples a linear dilution
response was observed. Mean recovery in the curves
was 101%, with a standard deviation of 7.1% (mini-
mum 79.7%, maximum 116%) (Figure 3).
Clinical performance
Method comparison Comparison of the Access GI
Monitor (CA19-9 antigen) assay on the UniCel DxI
800 Immunoassay System and the CA19-9 assay on
the Elecsys 2010 Immunology System, calculated on
all serum samples (ns1811), yielded a correlation
coefficient of Rs0.959, with a slope of 1.004 and an
intercept of q0.17.
A large number of samples (ns1765) were found
to have values up to 1000 kU/L. For this clinically rel-
evant group, an excellent correlation was still found.
The coefficient of correlation was Rs0.962, with a
slope of 1.006 and an intercept of q0.16. Finally, in
patients with GI Monitor values in the clinical decision
range up to 100 kU/L (ns1636), the coefficient of
correlation was Rs0.935, with a slope of 1.023 and an
intercept of q0.05 (Figure 4).
Healthy individuals For the Access GI Monitor, the
95th percentile URL of a healthy population (ns267)
was found at 23.1 kU/L. The value distribution ranged
from -0.8 to 87.0 kU/L. Mean was at 8.3 kU/L, median
at 6.0 kU/L. The 25th percentile was calculated at 3.7
kU/L, 97.5th percentile at 28.9 kU/L and 99th percentile
at 39.6 kU/L. Females had slightly higher levels (medi-
an at 6.8 kU/L, 95th percentile at 25.2 kU/L) than males
(median at 5.3 kU/L, 95th percentile at 17.3
kU/L). Both methods showed a very comparable dis-
tribution and a good correlation (Rs0.954, slope
1.124, intercept of –0.41) (Figure 5, Table 1).
Individuals with benign diseases Of 549 individuals
diagnosed with benign diseases, patients with benign
gastrointestinal diseases showed the highest levels
for the Access GI Monitor up to 500 kU/L (median at
13.4 kU/L, 95th percentile at 195.5 kU/L). Two patients
with end-stage renal disease had GI Monitor values
higher than 200 kU/L. The lowest levels were found
in benign breast diseases (median at 5.8 kU/L, 95th
percentile at 30.1 kU/L), which were in the range of
healthy individuals. For all benign diseases, both
methods showed comparable results and a good cor-
relation (Rs0.967, slope 0.979, intercept of q0.62).
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Figure 4 Method comparison of the GI Monitor with the reference method.
Correlation of Access GI Monitor (Beckman Coulter) and Elecsys CA19-9 (Roche Diagnostics) concentrations were calculated
(A) for the range -1000 kU/L and (B) for the range -100 kU/L. (C) Normalized differences from mean values were calculated
according to Bland and Altman.
Figure 5 Value distribution of the GI Monitor and reference method in controls.
(d) Dot plot of Access GI Monitor (Beckman Coulter) and (e) Elecsys CA19-9 (Roche Diagnostics) concentrations in serum
samples of healthy individuals and individuals with various benign diseases.
Details of value distribution are listed in Table 1 and
Figure 5.
Individuals with malignant diseases Of 995 individ-
uals diagnosed with malignant diseases, patients with
pancreatic cancer showed the highest levels for the
Access GI Monitor (median 233.8 kU/L, 95th percentile
at 13,902 kU/L), with maximum levels of more than
15,000 kU/L. Some extremely elevated values were
found in single individuals with colorectal, ovarian or
gynecological cancers too, but median and 95th per-
centiles were considerably lower than in pancreatic
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Table 1 GI Monitor concentrations in sera of cancer patients and controls.
Diagnosis n Method Median, Range, 95th percentile,
kU/L kU/L kU/L
Healthy individuals 267 Dxl 800 6.0 0.8–87.0 23.1
Elecsys 5.9 0.6–69.1 24.0
Benign gastrointestinal diseases 155 Dxl 800 13.4 0.8–497.0 195.5
Elecsys 13.4 0.6–495.0 173.4
Benign lung diseases 44 Dxl 800 10.5 0.8–66.0 59.7
Elecsys 7.2 0.6–51.9 46.7
Benign gynecological diseases 109 Dxl 800 7.4 0.8–179.9 51.9
Elecsys 8.7 0.6–132.0 53.1
Benign breast diseases 148 Dxl 800 5.8 0.8–158.0 30.1
Elecsys 8.7 0.6–193.0 31.7
Benign urological diseases 66 Dxl 800 13.8 0.8–551.5 84.2
Elecsys 13.5 0.6–534.0 91.4
Other benign diseases 27 Dxl 800 11.8 0.8–34.8 30.4
Elecsys 10.7 0.6–30.0 27.6
Gastric cancer 26 Dxl 800 9.3 0.8–811.0 644.2
Elecsys 13.4 1.3–699.0 572.0
Hepatocellular cancer 58 Dxl 800 55.8 0.8–397.8 209.6
Elecsys 61.7 0.6–461.0 331.4
Pancreatic cancer 62 Dxl 800 233.8 2.5–15,489 13,902
Elecsys 205.5 4.5–19,483 12,952
Colorectal cancer 113 Dxl 800 33.5 0.8–39,325 11,014
Elecsys 35.0 0.6–25,104 9224
Lung cancer 82 Dxl 800 18.9 0.8–855.2 652.3
Elecsys 17.3 0.6–1074 732.8
Ovarian cancer 81 Dxl 800 15.2 0.8–72,602 1298.3
Elecsys 16.6 0.6–95,184 1703.3
Gynecological cancer 57 Dxl 800 20.2 0.8–20,245 3174.1
Elecsys 22.5 0.6–18,200 3009.6
Breast cancer 416 Dxl 800 11.0 0.8–4934 84.3
Elecsys 11.2 0.6–4422 82.0
Urological cancer 57 Dxl 800 8.4 0.8–6883 102.1
Elecsys 10.1 0.6–4089 118.1
Prostate cancer 43 Dxl 800 8.4 2.7–130.0 53.7
Elecsys 9.5 2.5–123.0 50.4
Median, range and 95th percentile limit of the Access GI Monitor (Beckman Coulter) for healthy individuals, patients with
benign and malignant diseases. Comparison with Elecsys CA19-9 (Roche Diagnostics) concentrations.
cancer. Except prostate cancer, all cancer types were
associated with GI Monitor values up to 400 kU/L and
greater. In general, results of both methods were
very comparable and a good correlation was found
(Rs0.961, slope 1.004, intercept of q0.17). Details
of value distribution are listed in Table 1 and
Figure 6.
Sensitivity for cancer disease In addition to the com-
parison of the absolute concentrations of both meth-
ods in various patient groups with benign and
malignant diseases, the diagnostic capacity of the
Access GI Monitor (CA19-9 antigen) assay on the
UniCel DxI 800 Immunoassay System was tested by
ROC curves showing the profile of sensitivity and
specificity over the whole range of values and was
compared to that of the CA19-9 assay on the Elecsys
2010 Immunology System. According to the guide-
lines of the European Group on Tumor Markers
wEGTM, (33)x, all cancer types were compared with the
respective benign disorders as the relevant control
group.
Concerning their diagnostic capacity, both methods
showed very comparable results for all cancer types
investigated. This good diagnostic correlation was
expressed by the similar values for the AUC with
overlapping confidence intervals, as well as by the
sensitivity for cancer detection at the 95% specificity
of benign diseases (Table 2). Among all cancers, pan-
creatic cancer showed the highest AUC value for both
methods when compared with benign gastrointestinal
diseases (Access GI Monitor: AUC 0.827, Elecsys
CA19-9: AUC 0.850) and the highest sensitivity at 95%
specificity of benign gastrointestinal diseases (Access
GI Monitor: sensitivity 53.2%, Elecsys CA19-9: sensi-
tivity 58.1%). Most importantly, for GI Monitor values
above 500 kU/L, a sensitivity of 40.3% at a specificity
of 100% was reached, suggesting a diagnostic value
of high GI Monitor levels in the setting of suspicious
pancreatic lesions (Figure 7, Table 2). Otherwise, the
Access GI Monitor and Elecsys CA19-9, respectively,
showed diagnostic power for other cancers, such as
hepatocellular cancer, colorectal cancer, lung cancer,
ovarian cancer, breast cancer and other gynecological
cancers, too (Figure 8, Table 2).
Sensitivity for cancer disease in patients with normal
bilirubin values The evaluation of the diagnostic
power of the GI Monitor and Elecsys CA19-9, respec-
tively, was performed in a subgroup of patients with
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Figure 6 Value distribution of the GI Monitor and reference method in cancer patients.
(d) Dot plot of Access GI Monitor (Beckman Coulter) and (e) Elecsys CA19-9 (Roche Diagnostics) concentrations in serum
samples of individuals with various malignant diseases.
Table 2 Diagnostic capacity of GI Monitor for various cancer diseases.
Diagnosis n Method Sensitivity at 95% AUC Confidence
specificity vs. respective interval
benign diseases
Pancreatic cancer 62 Dxl 800 53.2 0.827 0.760–0.894
Elecsys 58.1 0.850 0.789–0.911
Gastric cancer 26 Dxl 800 15.4 0.440 0.310–0.570
Elecsys 7.7 0.482 0.354–0.610
Hepatocellular cancer 58 Dxl 800 6.9 0.682 0.600–0.763
Elecsys 6.9 0.718 0.640–0.795
Colorectal cancer 113 Dxl 800 25.7 0.626 0.557–0.696
Elecsys 25.7 0.633 0.564–0.702
Lung cancer 82 Dxl 800 26.8 0.689 0.596–0.782
Elecsys 31.0 0.715 0.625–0.805
Ovarian cancer 81 Dxl 800 22.2 0.613 0.530–0.697
Elecsys 24.7 0.614 0.530–0.698
Gynecological cancer 57 Dxl 800 31.6 0.666 0.570–0.762
Elecsys 36.8 0.650 0.552–0.748
Breast cancer 416 Dxl 800 16.3 0.674 0.625–0.723
Elecsys 15.9 0.600 0.552–0.649
Renal cancer 29 Dxl 800 3.6 0.416 0.299–0.533
Elecsys 0.0 0.429 0.312–0.546
Bladder cancer 28 Dxl 800 6.9 0.436 0.315–0.558
Elecsys 10.3 0.460 0.336–0.585
Survey on the diagnostic capacity of the Access GI Monitor (Beckman Coulter) for various cancer diseases when compared
with their respective benign diseases as control groups and comparison with the Elecsys CA19-9 (Roche Diagnostics). Area
under the curve (AUC) of the receiver operating characteristic curves and sensitivity at 95% specificity vs. the respective
benign diseases indicate the discriminating power.
normal bilirubin levels (-17.103 mmol/L), because the
well-known in vivo influence of cholestasis on serum
values of CA19-9 antigen often corresponds to ele-
vated serum bilirubin levels. While median and 95th
percentile levels remained constant in most benign
and malignant subgroups, lower levels of the GI Mon-
itor were observed in patients with benign gastroin-
testinal diseases (all patients: ns155, median 13.4
kU/L, 95th percentile 195.5 kU/L; patients with normal
bilirubin levels: ns89, median 10.6 kU/L, 95th percen-
tile 123.8 kU/L), in patients with hepatocellular cancer
(all patients: ns58, median 55.8 kU/L; patients with
normal bilirubin levels: ns25, median 37.6 kU/L) and
colorectal cancer (all patients: ns113, median
35.0 kU/L; patients with normal bilirubin levels: ns83,
median 28.7 kU/L), but not in patients with pancreatic
cancer (all patients: ns62, median 233.8 kU/L;
patients with normal bilirubin levels: ns37, median
244.8 kU/L). This means that the bilirubin levels were
relevant for GI Monitor values, and in a very similar
way, also for Elecsys CA19-9 values, in patients with
benign gastrointestinal diseases, as well as in those
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Figure 7 Diagnostic capacity of the GI Monitor and refer-
ence method for detection of pancreatic cancer.
Profiles of sensitivity and specificity over the whole range of
cut-off values are shown by receiver operating characteristic
(ROC) curves for pancreatic cancer (ns62) vs. benign gas-
trointestinal diseases (ns155). (d) Access GI Monitor (Beck-
man Coulter) and (e) Elecsys CA19-9 (Roche Diagnostics).
with hepatocellular and colorectal cancers, but not in
patients with pancreatic cancer. Thus, the diagnostic
power of the GI Monitor for most cancer diseases
remained unchanged, but was considerably improved
for pancreatic cancer vs. benign gastrointestinal dis-
eases by considering only sera with normal bilirubin
content (Access GI Monitor: AUC 0.910, Elecsys CA19-
9: AUC 0.913; Figure 9). Then, the sensitivity at 95%
specificity for pancreatic cancer vs. benign gastro-
intestinal diseases reached 67.6% for the Access GI
Monitor and 70.3% for Elecsys CA19-9.
Discussion
Several studies have shown that CA19-9 is the marker
of first choice for diagnosis of pancreatic cancer (8,
20–22). If no cholestatic gastrointestinal diseases,
such as liver cirrhosis, cholangitis, cholecystolithiasis
are present – which can also provoke elevated CA19-
9 levels (8, 9, 17–19) – preoperative and pretherapeu-
tic CA19-9 concentrations are helpful in suggesting
differential diagnosis of pancreatic cancer. Moreover,
prognostic relevance of pretherapeutic CA19-9-levels
for overall survival of pancreatic cancer patients
undergoing surgery and/or receiving systemic che-
mo- and/or radiotherapy was found repeatedly by
several groups (6, 23–25). Similarly, the usefulness of
CA19-9 for therapy monitoring as well as early detec-
tion of disease progression, in pancreatic cancer
patients is widely recognized and accepted (6, 26–31).
Besides pancreatic cancer, CA19-9 is detected in
colorectal, gastric, liver, gallbladder, lung, breast and
ovarian cancer tissues, as well as in the serum of
these patients (8–10). Diagnostic and/or prognostic
value of CA19-9 was reported, particularly for cholan-
giocellular cancer (34), colorectal cancer (35, 36) and
gastric cancer (37, 38).
In the present study, the new Access GI Monitor
assay, which uses the monoclonal antibody C192 for
detection of the CA19-9 antigen, was tested on its
analytical and clinical performance. The guidelines of
the EGTM (33) require a new diagnostic method to be
investigated for potential influence of organ-specific
and non-specific influences which might alter the
metabolism of the antigen. Further, the new method
has to be compared with a current accepted method
to demonstrate its superiority, or at least equivalence,
for the intended indication.
First, we therefore performed a thorough analytical
evaluation at five European centers, to test the basic
preconditions for routine application. Then, a large
panel of sera from 1811 individuals was investigated.
These individuals included healthy individuals,
patients with gastrointestinal and other benign dis-
eases and many patients with various cancer diseases
that might be relevant for differential diagnosis by
CA19-9. The entire clinical evaluation of the Access GI
Monitor was carried out in parallel with the Elecsys
CA19-9, a current standard method, using the same
sera from the same patients, to enable a fair compar-
ison of both methods.
The analytical performance for the GI Monitor assay
was very good with a low within-run, total and inter-
laboratory imprecision. Additionally, we observed
high recoveries during linearity upon dilution testing,
and no high-dose hook effect up to 114,920 kU/L.
Sample type interference studies demonstrated that
serum and lithium-heparinate plasma can be used
interchangeably. However, GI Monitor levels in EDTA
plasma and citrate plasma were approximately
20%–30% lower than in serum. Concerning sample
storage, it is important to note that freezing did not
affect the marker values, and long-term storage for
6 months at –208C still yielded stable results. Of clin-
ical relevance is the finding that endogenous interfe-
rents, such as hemoglobin, bilirubin, triglycerides and
rheumatoid factor, do not influence GI Monitor con-
centrations in vitro. However, as mentioned above, it
is well known that cholestatic diseases which are
often associated with high bilirubin levels can in vivo
cause considerable elevations of CA19-9 antigen in
serum (8, 9, 17–19).
Comparison of the Access GI Monitor with Elecsys
CA19-9 showed a very good correlation for all
patients and for the various subgroups investigated.
This observation is all the more valuable as the slope
and intercept were only minimal, meaning that the
absolute values of both methods were very compar-
able. Earlier studies which compared various CA19-9
methods reported significant systematic differences
among various systems (39). They also found no sim-
ilar clinical efficacy, though different cut-off values for
the various systems were used (39). Nevertheless, it
has to be pointed out that in single patients consid-
erable differences in the concentrations were
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Figure 8 Diagnostic capacity of the GI Monitor and reference method for detection of lung cancer, colorectal cancer, breast
cancer and ovarian cancer.
Profiles of sensitivity and specificity over the whole range of cut-off values are shown by receiver operating characteristic
(ROC) curves for (A) lung cancer (ns82) vs. benign lung diseases (ns44), (B) colorectal cancer (ns113) vs. benign gastro-
intestinal diseases (ns155), (C) breast cancer (ns416) vs. benign breast diseases (ns148), and (D) ovarian cancer (ns81) vs.
benign gynecological diseases (ns109). (d) Access GI Monitor (Beckman Coulter) and (e) Elecsys CA19-9 (Roche Diagnostics).
observed showing the necessity to plan carefully the
potential change of the CA19-9 antigen methods and
to measure CA19-9 antigen in parallel with both meth-
ods if kinetic interpretations are carried out.
In our study, healthy individuals had very low con-
centrations, as measured with both methods. Cut-offs
for the URLs were very comparable and were in the
range of the values indicated by both methods (Beck-
man Coulter 35 kU/L, Roche Diagnostics 27 kU/L).
Concentrations in sera of individuals diagnosed
with benign gastrointestinal, lung, breast, gynecolog-
ical diseases and other disorders were higher than in
healthy individuals. However, the differences were
only slight in benign lung, breast, gynecological, uro-
logical and other benign diseases, even if single indi-
viduals (e.g., with end-stage renal disease) reached
higher values. As expected, the highest CA19-9 levels
were observed in benign gastrointestinal diseases,
such as liver cirrhosis, cholangitis, hepatitis and pan-
creatitis, where single individuals reached values up
to 500 kU/L.
CA19-9 concentrations in patients suffering from
various cancers were also elevated. However, in
some cancer types, the medians and 95th percentiles
were comparable with those of benign diseases, e.g.,
for bladder, renal and prostate cancer. In contrast,
gastrointestinal, urological and gynecological cancer
demonstrated greater CA19-9 elevations, which
reached )20,000 kU/L in some patients.
The best diagnostic accuracy of the GI Monitor for
cancer detection against the relevant benign control
group was found for pancreatic cancer (AUC 0.827,
sensitivity at 95% specificity vs. benign gastrointesti-
nal controls 53.2%). Most impressively, for GI Monitor
values above 500 kU/L, a sensitivity of 40.3% at a
specificity of 100% was reached, meaning that, for
those levels and in this subgroup of patients, the GI
Monitor had diagnostic properties. This excellent
differential diagnostic result cannot be achieved by
other established tumor-associated antigens and
underlines the high relevance of CA19-9 antigen in
pancreatic cancer. Importantly, GI Monitor results
also correspond very well with the diagnostic accu-
racy of the CA19-9 reference method for cancer detec-
tion, as shown by similar AUC values and overlapping
confidence intervals. Though the diagnostic power of
the GI Monitor is lower for other tumor types, it has
to be pointed out that for colorectal, lung, ovarian and
gynecological cancer the AUC was still higher than
0.6 and the sensitivity at 95% specificity vs. the rele-
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Figure 9 Diagnostic capacity of the GI Monitor and refer-
ence method for detection of pancreatic cancer with normal
bilirubin levels.
Profiles of sensitivity and specificity over the whole range of
cut-off values are shown by receiver operating characteristic
(ROC) curves for pancreatic cancer (ns37) vs. benign gas-
trointestinal diseases (ns89) with normal bilirubin levels
(-10 mg/L). (d) Access GI Monitor (Beckman Coulter) and
(e) Elecsys CA19-9 (Roche Diagnostics).
vant benign control group was higher than 20% –
once again, both methods were very comparable
even if small differences were observed in some ROC
curves, possibly due to slightly different epitope bind-
ing sites or different compositions of the assays. This
diagnostic performance in cancer types for which
CA19-9 was not considered as a relevant marker sug-
gests there may be value in including CA19-9 with
other diagnostically relevant markers in future multi-
parametric analyses. In combination with well-known
markers, e.g., CYFRA 21-1, carcinoembryonic antigen,
neuron-specific enolase and progastrin-releasing pep-
tide in lung cancer, CA19-9 and other mucin markers
might be helpful to further improve the diagnostic
accuracy (40).
The diagnostic power of the GI Monitor was also
analyzed in a subgroup of patients with normal bili-
rubin levels below 10 mg/L, to study the in vivo influ-
ence of cholestasis on serum values of CA19-9
antigen more precisely. In patients with benign gas-
trointestinal diseases and hepatocellular and colorec-
tal cancers, the findings of lower GI Monitor levels
confirmed an influence of cholestasis on GI Monitor
values. In contrast to this, GI Monitor levels remained
unchanged in all other benign and malignant dis-
eases, including pancreatic cancer. As a consequence,
the diagnostic power of the GI Monitor for pancreatic
cancer vs. benign gastrointestinal diseases was fur-
ther improved. It is noteworthy to mention that bili-
rubin levels had a similar influence on the Access GI
Monitor and Elecsys CA19-9 assays, and the sub-
group analysis showed very comparable results for
both methods.
Conclusions
The Access GI Monitor is a new assay based on an
alternative antibody for CA19-9 antigen detection. The
Access GI Monitor provides very good methodologi-
cal characteristics for use in routine laboratory and
demonstrates an excellent analytical and clinical cor-
relation with the Elecsys CA19-9. The GI Monitor
shows a high diagnostic accuracy in pancreatic cancer
and it is a valuable marker in the management of this
disease. Our results also suggest a clinical value of
the GI Monitor in gastrointestinal (colorectal and
gastric), gynecological (ovarian and endometrial)
and lung cancers. If the CA19-9 antigen method is
changed, parallel measurements of CA19-9 with both
methods for an appropriate time span are strongly
recommended.
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